Remdesivir treatment reduces the risk for 30-day COVID-19-related hospital readmission among all patients discharged alive from initial hospitalization.
In utero exposure to COVID-19 infection during pregnancy is not associated with impaired neurodevelopmental outcomes in children through age 24 months.
DTG/FTC was effective for long-term HIV management with a good safety profile, suggesting it may be a viable alternative option to 3-drug ART regimens.